Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Quantitative Aspects of Drug-Receptor Interaction01:30

Quantitative Aspects of Drug-Receptor Interaction

1.7K
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
1.7K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
Protein-protein Interfaces02:04

Protein-protein Interfaces

14.4K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
14.4K
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

7.2K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
7.2K
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

948
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
948
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genomic landscape of drug binding and pharmacogenetic variation across diverse populations using SNPdrug3D.

Nature communications·2026
Same author

Ferroptosis vulnerability of enzalutamide resistant prostate cancer conferred by ACSL4 overexpression and GPX4 antagonism.

Cell death & disease·2026
Same author

DeepDrugDiscovery identifies blood-brain barrier permeable autophagy enhancers for Alzheimer's disease.

Nature biomedical engineering·2026
Same author

Covalent Organic Framework with Acid Precipitation Enhances Microprotein Enrichment and Discovery of Ferroptosis-Associated Microproteins.

Analytical chemistry·2026
Same author

A Pseudomonas aeruginosa quorum-sensing metabolite manipulates macrophage ferroptosis through a methylation pathway.

Nature communications·2025
Same author

A Model for the Development of Alzheimer's Disease.

Genomics, proteomics & bioinformatics·2025
Same journal

PFASGroups: An Open-Source Framework for Automated Identification, Structural Classification, and Prioritization of Per- and Polyfluoroalkyl Substances.

Journal of chemical information and modeling·2026
Same journal

DeepKbhb: Context-Aware Prediction of Human Lysine β-Hydroxybutyrylation Sites.

Journal of chemical information and modeling·2026
Same journal

HyperDC: A Non-Uniform Hypergraph Framework for Dual- and Higher-Order Drug Combination Recommendation Across Diverse Complex Diseases.

Journal of chemical information and modeling·2026
Same journal

Correction to "AstraMEV (AI-Guided Structural Assembly of Multi-Epitope Vaccines) Against Infectious Bronchitis Virus".

Journal of chemical information and modeling·2026
Same journal

MolPy: A Large Language Model-Friendly Toolkit for Reactive Topology Editing in Polymer Simulations.

Journal of chemical information and modeling·2026
Same journal

Molecular Mechanisms of KIT Receptor Dimerization and Oncogenic Activation Revealed by Multiscale Simulations.

Journal of chemical information and modeling·2026
See all related articles

Related Experiment Video

Updated: Jan 9, 2026

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
05:50

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

1.4K

BioFusionDTI: Assimilating Graph and Sequence Modalities for Generalizable Drug-Target Interaction Prediction.

Qiufen Chen1, Guanyan Nie2, Xiaoli Li3

  • 1Department of Chemistry, School of Science, Southern University of Science and Technology, Shenzhen 518055, Guangdong, China.

Journal of Chemical Information and Modeling
|December 9, 2025
PubMed
Summary
This summary is machine-generated.

BioFusionDTI, a new multimodal deep learning framework, accurately predicts drug-target interactions (DTIs) using integrated graph and sequence data. It improves generalization and interpretability for drug discovery, outperforming existing methods.

More Related Videos

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.4K
Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

3.6K

Related Experiment Videos

Last Updated: Jan 9, 2026

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
05:50

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

1.4K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.4K
Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

3.6K

Area of Science:

  • Computational Biology
  • Drug Discovery
  • Artificial Intelligence

Background:

  • Accurate drug-target interaction (DTI) prediction is crucial for efficient drug discovery and repurposing.
  • Current deep learning models struggle with generalization in cold-start scenarios and lack interpretability.

Purpose of the Study:

  • To develop BioFusionDTI, a multimodal deep learning framework to enhance DTI prediction accuracy and interpretability.
  • To address limitations in generalization and interpretability of existing deep learning models for DTIs.

Main Methods:

  • Integrating graph-based (using Graph Convolutional Networks - GCNs) and sequence-based (using Convolutional Neural Networks - CNNs) representations of drugs and proteins.
  • Employing a Bilinear Attention Network (BAN) for fine-grained cross-modal interaction capture.
  • Utilizing pretrained biomolecular language models for sequence embeddings.

Main Results:

  • BioFusionDTI consistently outperformed state-of-the-art baselines across multiple benchmark datasets (SNAP, DRH, Kinase) in various settings (warm, cold-drug, cold-protein).
  • Ablation studies confirmed the effectiveness of the fusion strategy, with the BAN module significantly contributing to performance.
  • Attention visualizations identified biologically plausible interaction sites, consistent with molecular docking results.

Conclusions:

  • BioFusionDTI offers a robust and interpretable solution for predicting drug-target interactions.
  • The framework demonstrates improved generalization capabilities, particularly in challenging cold-start scenarios.
  • BioFusionDTI advances the field of computational drug discovery and repositioning.